MICOT PHARMA-B (02335): All enrolled participants have completed the Phase III clinical trial of MT1013
MICOT PHARMA-B (02335) announced that in the pivotal Phase III clinical trial of the Company's core product MT1013, all enrolled participants have completed the study treatment and all protocol-specified follow-up procedures, and have exited the study.
MICOT PHARMA-B (02335) announced that in the pivotal Phase III clinical trial of the Company's core product MT1013, all enrolled participants have completed the study treatment and all protocol-required follow-up procedures, and have exited the study.
Related Articles
ZHAOKE OPHTH-B (06622) repurchased 21,500 shares on November 6 for approximately HK$42,800.
CHINA AOYUAN (03883) issues 21,047,600 new shares upon conversion of mandatory convertible bonds.
ZHENRO PPT (06158) suspended trading on the morning of November 9 pending an announcement of inside information.
ZHAOKE OPHTH-B (06622) repurchased 21,500 shares on November 6 for approximately HK$42,800.
CHINA AOYUAN (03883) issues 21,047,600 new shares upon conversion of mandatory convertible bonds.
ZHENRO PPT (06158) suspended trading on the morning of November 9 pending an announcement of inside information.
